Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 567

1.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

2.

Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.

Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.

3.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

4.

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.

Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.

5.

Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.

Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y.

Int J Cancer. 2013 Nov;133(9):2225-33. doi: 10.1002/ijc.28202. Epub 2013 May 9.

6.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

7.

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.

Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y.

Oncotarget. 2014 Mar 30;5(6):1646-56.

8.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

9.

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.

Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P.

PLoS One. 2011 Apr 28;6(4):e19059. doi: 10.1371/journal.pone.0019059.

10.

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.

Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y, Fu X, Sartor O, Dong Y, Zhang H.

Oncotarget. 2015 Sep 15;6(27):23358-71.

11.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

12.

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G.

Cancer Res. 2012 May 1;72(9):2176-82. doi: 10.1158/0008-5472.CAN-11-3980. Epub 2012 Mar 12.

13.

MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.

Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S.

Oncotarget. 2015 Jan 1;6(1):288-304.

14.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

15.

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.

Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25.

16.

Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

Krause WC, Shafi AA, Nakka M, Weigel NL.

Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.

17.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
18.

Are androgen receptor variants a substitute for the full-length receptor?

Lu J, Van der Steen T, Tindall DJ.

Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10. Review.

PMID:
25666893
19.

Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.

Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.

Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.

PMID:
27550197
20.

Androgen receptor splice variants in the era of enzalutamide and abiraterone.

Nakazawa M, Antonarakis ES, Luo J.

Horm Cancer. 2014 Oct;5(5):265-73. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22. Review.

Supplemental Content

Support Center